ResearcherNational Cancer Center Research InstituteNo recent work listed
Yuki Yamamoto
Matched on ORCID iD 0000-0001-7733-3741; OpenAlex author ID A5012899523. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper
Papers 3
- A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells. Co-author DOI 10.21873/anticanres.11730↗
- A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. Co-author DOI 10.1016/j.jconrel.2014.07.053↗
- Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer. Co-author DOI 10.1111/cas.12332↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kazunori Aoki · 3 shared papers, 2014–2017 · strength 0.15
- Paper A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells. DOI 10.21873/anticanres.11730↗
- Paper A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. DOI 10.1016/j.jconrel.2014.07.053↗
- Paper Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon… DOI 10.1111/cas.12332↗
- Nobuyoshi Hiraoka · 2 shared papers, 2014–2017 · strength 0.11
- Paper A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells. DOI 10.21873/anticanres.11730↗
- Paper A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. DOI 10.1016/j.jconrel.2014.07.053↗
- Masaki Nagasato · 1 shared paper, 2017 · strength 0.07
- Kouichirou Aida · 1 shared paper, 2014 · strength 0.04
- Teruhiko Yoshida · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.